In this issue of Blood, a new study by Kiyasu et al used a double-staining technique to identify cell-specific programmed cell death ligand 1 (PD-L1) expression in 1253 diffuse large B-cell lymphoma (DLBCL) samples and analyzed the findings together with programmed death-1 (PD-1) expression in tumorinfiltrating lymphocytes (TILs) and clinical outcomes, providing new insights into the role of the PD-1/PD-L1 pathway in DLBCL. 1 T he pathway consisting of the PD-1 receptor (CD279) and its ligands PD-L1 and PD-L2 (B7-DC; CD273) plays a vital role in peripheral tolerance 2 but also mediates inhibitory signals that compromise antitumor immunity. Targeting the PD-1/PD-L1 pathway has shown clinical efficacy in solid tumors 3 but also in Hodgkin and non-Hodgkin lymphoma. 4, 5 In solid tumors, expression of PD-L1 in cancer cells is a prognostic factor of adverse clinical outcomes and an independent predictive factor of clinical response to therapeutic targeting of the PD-1/PD-L1 checkpoint. 3, 6 Kiyasu et al assessed the expression of PD-L1 in 1253 DLBCL samples using a double-immunostaining technique identifying PD-L1 and PAX-5 together in order to determine whether PD-L1 is expressed on lymphoma cells (a pattern defined as PD- In contrast, there is no significant difference in overall survival between mPD-L1 1 and mPD-L1 2 DLBCL.
These observations reveal the significance of identifying the cell-specific expression of PD-L1 in the DLBCL microenvironment. In many cancer types, tumor-specific expression of PD-L1 is a significant determinant of adverse prognosis and a regulator of PD-1-mediated immunosuppression. In such tumors, the number of PD-1
1 TILs positively correlates with tumor-specific PD-L1 expression and is a poor prognostic factor. 7 In contrast to these observations in solid tumors, the presence of a high number of PD-1 1 TILs is a favorable prognostic factor in patients with DLBCL and follicular lymphoma, whereas a low number of PD-1
1
TILs is associated with a higher risk of histologic transformation. 8, 9 The study by Kiyasu et al provides new insights regarding the expression of the PD-1/PD-L1 pathway components and their implications in DLBCL. An important point that should be taken into consideration when analyzing the significance of PD-1 expression in TILs of B-cell malignancies is that PD-1 is normally expressed at high levels on germinal center follicular helper T cells. 10 Therefore, Expression of PD-1 in TILs of DLBCL might also be regulated by other mechanisms. Tumor antigens can be presented to T cells by direct presentation by tumor cells and by indirect presentation by antigen-presenting cells (APCs). Because B cells have natural APC function, it is conceivable that lymphoma B cells might function as APCs. Thus, both lymphoma cells and APCs of the DLBCL microenvironment may induce activation of TILs, leading to the expression of activation markers, including PD-1. Such effects would be less pronounced in the presence of PD-L1, which inhibits T-cell activation and expansion (see figure) . Consistent with this hypothesis, the number of PD-1 1 TILs is significantly lower in DLBCL that expresses high levels of PD-L1 compared with DLBCL with low PD-L1 expression in the tumor microenvironment. 1 An important finding of the study is that expression of PD-L1 on lymphoma cells but not on other cells of the DLBCL microenvironment has a significant impact on clinical outcomes. These results are reminiscent of previous observations in patients with solid tumors, where tumorspecific expression of PD-L1 is a negative prognostic determinant, and suggest that the PD-1/PD-L1 pathway may preferentially mediate its immunosuppressive effects during direct presentation of tumor antigens. However, in contrast to solid tumors, PD-L1
1 DLBCLs have low numbers of PD-1 1 TILs. It will be critical to determine whether anti-PD-L1 blocking antibodies might lead to superior outcomes as compared with anti-PD-1 antibodies in this subgroup of DLBCL patients. Because mPD-L1 expression does not have an impact on survival, it will be important to determine whether targeting the PD-1/PD-L1 pathway has any therapeutic benefit in this patient subgroup. Thus, identification of cell-specific expression of PD-L1 in DLBCL might have prognostic significance but might also guide treatment decisions. The present study opens new avenues in the research of PD-1/PD-L1 biology in lymphomas and suggests that the regulation of this pathway is distinct and more complex in the cellular microenvironment of B-cell malignancies than in solid tumors. Conflict-of-interest disclosure: The author declares no competing financial interests. n
